Clinical trials
Progressive Multiple Sclerosis clinical trials
Below are recruiting progressive multiple sclerosis clinical trials, each written for real people, not researchers. We’re tracking 133 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07135752Recruiting
Comparing digital tests in people with early MS or MRI signs
This trial studies whether digital tests can detect early changes in people with radiologically isolated syndrome (RIS) or multiple sclerosis (MS) who have normal neurological exams. It may help identify subtle symptoms earlier.
NiceAges 18–60 - NCT07353216Recruiting
Testing ofatumumab for relapsing multiple sclerosis
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
Guangzhou, GuangdongAges 18 years+ - NCT06951919Recruiting
HOBSCOTCH study for memory help in MS
This trial tests a program called HOBSCOTCH to help people with MS who have memory or thinking problems. It also includes a caregiver who supports them.
Lebanon, New HampshireAges 20–75 - NCT06782724RecruitingPhase 2
Psilocybin therapy for distress in advanced illness
This trial tests whether a single dose of psilocybin (a psychedelic medicine) can help reduce depression and distress in people with advanced lung disease, ALS, multiple sclerosis, or Parkinson's. You would receive preparation, the drug, and follow-up support in a safe, supervised setting.
PragueAges 18 years+ - NCT02795052Recruiting
Stem cell treatment trial for nerve injury
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
Westport, ConnecticutAges 18 years+ - NCT05395624RecruitingPhase 1/Phase 2
Safety imaging study of a PET tracer in ALS, Alzheimer, MS, Parkinson
This early-phase study tests the safety of a radioactive tracer (“18F-OP-801”) and how the tracer moves through the body (biodistribution) in people with ALS, Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and in healthy volunteers. It also measures how the body processes the tracer (“pharmacokinetics”) to support future studies.
San Francisco, CaliforniaAges 18–80 - NCT06267781Recruiting
MS progression and immune cells after bone marrow transplant and other therapies
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
MilanAges 18 years+ - NCT07361094RecruitingPhase 1
CAR-T therapy for autoimmune disease after prior treatment
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It is for people with certain autoimmune diseases (like lupus or scleroderma) that have not responded well to standard treatments or have relapsed after prior cell therapy.
BeijingAges 18–70 - NCT06529406RecruitingPhase 4
Switching from B-cell therapy to ozanimod in MS
This study tests whether people with stable MS who have been on a B-cell depleting therapy for at least 2 years can safely switch to a daily pill called ozanimod. It aims to see if this switch keeps MS under control and may be more convenient.
Aurora, ColoradoAges 18 years+ - NCT05877963RecruitingPhase 3
Ublituximab treatment plan for relapsing multiple sclerosis
This Phase 3 trial tests the safety and effectiveness of a modified treatment plan using ublituximab for relapsing multiple sclerosis. It also studies how the drug behaves in the body and aims to improve disease control while monitoring side effects.
Birmingham, AlabamaAges 18–65 - NCT06143514Recruiting
Study of BRIUMVI in breast milk
This study looks at how much BRIUMVI (ublituximab) gets into breast milk. It helps understand if the drug is safe for breastfed babies whose mothers are already taking it for relapsing multiple sclerosis.
San Francisco, CaliforniaAges 18 years+ - NCT07710105Recruiting
Ocrevus for MS: A Real-World Study
This study will follow people with multiple sclerosis (MS) who are starting or restarting a treatment called Ocrevus (ocrelizumab). The goal is to understand how well it works in real life over 12 months. Participants will receive Ocrevus as part of their usual care and complete surveys about their experience.
Chicago, IllinoisAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT05957913Enrolling by invitationPhase 2
Testing antiviral drugs to control Epstein-Barr virus in MS
This Phase 2 study tests whether certain antiviral medicines can reduce Epstein-Barr virus (EBV) activity. If you have multiple sclerosis and evidence of EBV infection, the results may help clarify new ways to target EBV-related disease activity.
Boston, MassachusettsAges 18 years+ - NCT04650321RecruitingPhase 4
Home infusions of ocrelizumab for some people with MS
This study looks at giving ocrelizumab treatments at home instead of in a clinic for people with MS. It’s meant to see if this approach is practical and acceptable while you keep receiving a medicine your MS doctor thinks you should continue.
Centennial, ColoradoAges 18–55 - NCT04876339Recruiting
Sound-based training to improve walking after brain illness
This study tests whether using special sounds (sonification) during gait training can improve walking for people with stroke, Parkinson’s disease, or multiple sclerosis. It may help your walking speed, stamina (fatigue), and overall walking pattern.
PaviaAges Up to 80 years - NCT04933552Recruiting
Safety study of Mayzent during pregnancy for babies
This study follows pregnant people with multiple sclerosis (MS) who took Mayzent (siponimod) to understand safety for pregnancy outcomes. It compares them with other groups to see whether there are any differences in birth results.
La Jolla, CaliforniaAges Any age - NCT05380856Recruiting
Sacral nerve stimulation for bladder, bowel, and sexual symptoms
This trial studies whether sacral neuromodulation (a device that sends mild nerve signals) can improve bladder, bowel, and sexual symptoms caused by nerve problems. It is for people whose current bladder treatments have not worked well enough.
Odense, FynAges 18–80 - NCT05433103Recruiting
Blood flow restriction training for veterans with multiple sclerosis
This trial tests whether a special exercise method that briefly limits blood flow to the legs can improve strength and walking ability in people with multiple sclerosis (MS). If you have walking limitations, it may help you build fitness with less heavy resistance training—but you must be able to safely use a pressure cuff during testing.
Aurora, ColoradoAges 18–75 - NCT05482906Recruiting
Smartphone and MRI study for people with multiple sclerosis
This study looks at how information from a brain/spinal MRI and a smartphone relates to walking and daily function in people with multiple sclerosis (MS). It may help researchers understand what signals predict changes over time.
Nantes, Loire-AtlantiqueAges 18 years+ - NCT05634967Recruiting
Kesimpta pregnancy registry for pregnant people with MS
This registry collects information about pregnancy outcomes in people with multiple sclerosis (MS) who have taken Kesimpta (ofatumumab) during pregnancy or shortly before it. It may help doctors better understand safety and developmental outcomes for babies.
La Jolla, CaliforniaAges 18–100 - NCT05999604RecruitingPhase 3
Yearly vs every-6-month infusions for active MS
This study compares receiving ocrelizumab infusions every 6 months versus once a year for people with active MS who have already been on treatment for 2 years. The goal is to see if yearly infusions work just as well to keep the disease quiet on MRI scans.
CréteilAges 18 years+ - NCT06062693Recruiting
Home Hand Training with Sensors for Better Dexterity
This study tests a new home-based hand training system using sensors to help improve hand movement and dexterity in people with Parkinson's, multiple sclerosis, or stroke. It also includes healthy volunteers for comparison.
LucerneAges 18–99 - NCT06434571RecruitingPhase 2
Comparing two sleep treatments for people with MS
This trial tests if talking with a sleep coach by video is better than a web-based program for improving sleep, reducing fatigue, and protecting the brain in people with multiple sclerosis (MS). Both treatments focus on changing thoughts and habits around sleep.
Kansas City, KansasAges 18–65
Hear when a new Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progressive multiple sclerosis?
- Yes. Clin2 currently lists 133 recruiting progressive multiple sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progressive multiple sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progressive multiple sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis (MS) - Relapsing-remitting
- Relapsing Multiple Sclerosis
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.